Summary
From the hospital to pediatric offices to educational programs, Carilion Children's is all about kids. Our mission is to improve the health of all kids—in every community we serve, in hundreds of different ways. We're here with clinical expertise and compassionate care to make sure each generation is healthier than the last.
About the department
Icon Blurb
Virginia Tech Carilion Partnership
The Department of Pediatrics at Carilion Clinic and the Virginia Tech Carilion School of Medicine is a team of 90 providers who treat infants, children and adolescents in pediatric medicine practices, at specialty clinics and at Carilion Children's Hospital. The department's mission is to improve the health and well-being of all children in our community. We work to meet our mission by leveraging research, education, advocacy, access and community health programs and partnerships at the local, regional, state and national levels. Our community of approximately 1 million people is served by Carilion Clinic, with Carilion Children's having more than 100,000 medical encounters each year. Our department strongly supports the concept of integrated teams of health professionals. We see medical students as an important part of health care teams that also include physicians, residents, physician assistants, nurses, respiratory therapists, social workers and child life specialists, among others.
Mission Goals Strengths

ALL KIDS

  • Our mission is to improve child health and well-being in the communities we serve.

ALL SERVICES

  • Carilion Children's employs nearly 500 medical professionals who specialize in caring for children. 

ALL IN

  • Carilion Children's is a group of medical professionals, organizations and community members who have come together to care for children in our region.
Message From Leadership

Carilion Children's Professional REACH Network exists to share up-to-date research, education, advocacy opportunities and access initiatives with regional clinicians who are working to improve child health.

 

 

.

Message From Leadership Image or Video
image
Donald W. Kees, M.D.
Caption

Donald W. Kees, M.D., interim chair of Pediatrics, Carilion Children's Hospitalist

Dept Spec Program Size
92-bed Children's Hospital (HwH)
350 employed skilled professionals
Dept Spec Specialties within Department
Pediatric Allergy and Immunology
Pediatric Behavioral Medicine
Pediatric Cardiology
Pediatric Therapies
Child Development
Pediatric Endocrinology
Pediatric Gastroenterology
General Pediatrics
Clinical Genetics
Pediatric Hematology and Oncology
Neonatology
Pediatric Neurology
Pediatric Palliative Care
Pediatric and Adolescent Gynecology
Pediatric Critical Care
Pediatric Pulmonology
Pediatric Hospital Medicine
Dept Spec Areas We Serve
Roanoke
Lynchburg
Christiansburg
Daleville
Dept Spec Quick Facts
Largest dedicated Pediatric In-patient hospital in southwest Virginia
Third-largest Neonatal Intensive Care Unit in Virginia
First regional Emergency Department devoted to caring for acutely ill and injured children
Only Pediatric Intensive Care Unit in western Virginia
Dept Spec Awards
4-time Magnet-dedicated facility, Children's Hospital
Gallery Images
CC Logo
Youtube Ids
PDvaKGevQsY
Overview

Carilion Children's offers the region's only children's hospital providing intensive care, outpatient services and primary care to southwestern Virginia, West Virginia, Tennessee and North Carolina. Our full-service 92-bed "hospital within a hospital" includes a regional level IIIB Neonatal Intensive Care Unit (NICU) for 60 newborns, a Pediatric Intensive Care Unit (PICU) and an inpatient unit, all specially designed for children. Carilion Children's is western Virginia's only Pediatric Level 1 Trauma Center with advanced medical transport units and a emergency department devoted to acutely ill or injured children. 

Display Images First
Off
News
News Block
image
Childhood Adversity
Header
Building Resilience in Childhood to Battle Adversity
Summary
Originally presented by J. Eric Vance, M.D., associate professor in Psychiatry, Carilion Clinic, VTCSOM, at Carilion Children's Grand Rounds.

Learning Objectives:
1. Identify common risk factors and protective factors for child development.
2. Describe neuroendocrine and brain pathways for stress and resilience.
3. Recommend specific interventions and medical approaches to build resilience.

Category 1 CME credit has been approved for this enduring material from January 1 through December 31, 2019. Click the notes section in the video for the CME link.
News Block
image
A Sweeping Review
Header
Primary Ciliary Dyskinesia: A Sweeping Review
Summary
Originally presented at Carilion Children's Grand Rounds by Andrea Garrod, M.D., assistant professor of Pediatrics, Division of Pediatric Respiratory Medicine, UVA Learning

Objectives:
1. Identify patients with clinical features consistent with primary ciliary dyskinesia (PCD)
2. Differentiate clinical, diagnostic, and prognostic features between cystic fibrosis and PCD
3. Recite the appropriate work up to make the diagnosis of primary ciliary dyskinesia

Category 1 CME credit has been approved for this enduring material from January 1 through December 31, 2019. To receive CME credit for watching this video, click on the survey in the "notes" section of the video.
Add Link or Upload FIle
News Block
image
Hellen Taussig
Header
Names & Faces from Pediatrics' Past
Summary
Presented at Carilion Children's Grand Rounds by: Hugh Craft, M.D., M.P.H., F.A.A.P., Carilion Pediatric Associates, Carilion Children's

Learning Objectives:
1. Describe some important figures in the history of pediatrics
2. Describe some important historical advances in pediatrics

Category 1 CME credit has been approved for this video. To receive credit please complete the survey in the notes section of this video.
Add Link or Upload FIle
Publications
Our Technology
Additional Technology Info
Research
Research Summary
Carilion Children's faculty oversee a range of clinical trials.
additional html blurb

Pediatric Oncology

Newly Diagnosed AML

A Phase III randomized trial for patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for patients with high allelic ratio FLT3/ITD.
PROTOCOL ID
COG # AAML1031

Protocol Description

This study is for newly diagnosed patients with acute myeloid leukemia (AML). AML is a cancer of the bone marrow, the spongy tissue inside the bones of the body where blood cells are made.

Eligibility Criteria

  • Patients must be less than 30 years of age at the time of study enrollment
  • Be newly diagnosed with AML
  • Agree to have bone marrow specimens sent to special COG labs prior to the start of treatment and at various times during treatment
  • Patients with Down syndrome are not eligible

Primary Investigator: Mandy Atkinson, M.D.

Contact

Wendy McCarty, Clinical Research Coordinator
540-981-7376
wpmccarty@carilionclinic.org

Newly Diagnosed Ependymoma

A Phase III randomized trial of post-radiation chemotherapy in patients with newly diagnosed ependymoma ages 1 to 21 years.
PROTOCOL ID
COG # ACNS0831

Protocol Description

This study is for patients newly diagnosed with ependymoma. Ependymoma is a type of cancer that occurs in the brain. This slow-growing tumor begins in cells that line the fluid-filled spaces of the brain (called ventricles) or the fluid-filled space down the center of the spinal cord (the central canal). The current standard of treatment for newly diagnosed ependymoma includes surgery to remove as much of the tumor as possible, and radiation therapy.


This study wants to see if a short course of chemotherapy therapy can kill any remaining tumor cells for patients whose tumor was only partially removed by surgery. Treatment with chemotherapy after surgery is experimental. This study also wants to see if patients whose remaining tumor was killed by the short course of chemotherapy and/or removed by a second surgery and whose tumor was not in the upper part of the brain and does not have favorable-looking cells. See if treatment with chemotherapy after radiation therapy will work better than standard treatment to keep the tumor from coming back. Treatment with chemotherapy after radiation therapy is experimental.

Eligibility Criteria

  • Patients must be greater than 12 months of age and less than 21 years of age at the time of study enrollment
  • Patients must be newly diagnosed with intracranial ependymoma. Patients with classic ependymoma (WHO II) or anaplastic ependymoma (WHO III) are eligible, as are various subtypes described as clear cell, papillary, cellular or a combination of the above.
  • Patients with evidence of metastatic disease by MRI or CSF cytology are NOT eligible

Primary Investigator: Mandy Atkinson, M.D.

Contact

Wendy McCarty, Clinical Research Coordinator
540-981-7376
wpmccarty@carilionclinic.org

Newly Diagnosed High-Risk B Precursor ALL

A Phase III randomized trial for newly diagnosed high-risk B-precursor acute lymphoblastic leukemia (ALL) testing clofarabine (IND # 73789, NSC # 606869) in the very high risk stratum.
PROTOCOL ID
COG # AALL1131

Protocol Description

This study is for newly diagnosed high-risk and very high-risk acute lymphoblastic leukemia (ALL) with or without Down Syndrome. Leukemia is cancer of blood cells. It develops in the bone marrow, which is the soft, spongy center of the bones that produces the three major blood cells.

Eligibility Criteria

Patients must be enrolled on AALL08B1 prior to enrollment on AALL1131.
White Blood Cell Count (WBC) Criteria

  • Age 1-9.99 years: WBC ³ 50 000/_L
  • Age 10-30.99 years: any WBC
  • Age 1-30.99 years: any WBC with:
    • Testicular leukemia
    • CNS leukemia (CNS3)
    • Steroid pretreatment

Primary Investigator: Mandy Atkinson, M.D.

Contact

Wendy McCarty, Clinical Research Coordinator
540-981-7376
wpmccarty@carilionclinic.org

For additional information on Children's Oncology studies, please visit Children's Oncology Group.

Newly Diagnosed Standard Risk B Precursor ALL

Treatment for patients with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia (ALL).
PROTOCOL ID
COG # AALL0932

Protocol Description

This study is for patients with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia (ALL)

Eligibility Criteria

•    Patients must have newly diagnosed NCI standard risk B-precursor ALL
•    Patients must be older than 365 days and younger than 10 years of age
•    Patients must be enrolled on AALL08B1 prior to enrollment on AALL0932
•    Patients must have an initial white blood count of less than 50,000
•    Patients with Down Syndrome are eligible

Primary Investigator: Mandy Atkinson, M.D.

Contact

Wendy McCarty, Clinical Research Coordinator
540-981-7376
wpmccarty@carilionclinic.org

Treatment of Children with All Stages of Hepatoblastoma

PROTOCOL ID
COG # AHEP0731

Protocol Description

This study is for patients with hepatoblastoma. Hepatoblastoma is a type of cancer that occurs in the liver. Researchers now know that there are some features of hepatoblastoma that may help predict how children will respond to therapy. Factors that affect how well a child with hepatoblastoma will do include:

  • Whether the tumor can be completely removed by surgery
  • Whether the tumor or cancer cells have spread to other parts of the body (metastasized)
  • How quickly a protein in the blood called alpha-fetoprotein (AFP) is decreased during treatment for hepatoblastoma; AFP is often very high in certain cancers, such as hepatoblastoma
  • The appearance of tumor cells under the microscope

Researchers know that children need different treatments based on the factors associated with the tumor. These factors determine the risk of the tumor coming back. This study will group children as having a very low-risk, low-risk, intermediate-risk or high-risk disease. This study will try to learn more about the factors that lead to a good or a poor chance of recovery (prognosis) for children. We want to develop effective treatments that will increase the overall success rate and decrease the side effects of the therapy.

Eligibility Criteria

  • Patients must be ≤ 21 years of age at the time of diagnosis
  • Patients may have had surgical resection of some or all sites of hepatoblastoma prior to enrollment
  • Patients must be newly diagnosed with histologically-proven hepatoblastoma except for patients too ill to undergo a biopsy safely

Primary Investigator: Mandy Atkinson, M.D.

Contact

Wendy McCarty, Clinical Research Coordinator
540-981-7376
wpmccarty@carilionclinic.org

Pediatric Gastroenterology

Eosinophilic Esophagitis (SHIRE 301)

Oral budesonide suspension (OBS) in adolescent and adult subjects (11-55 years of age, inclusive) with eosinophilic esophagitis: A Phase III randomized, double-blind, placebo-controlled study.

Protocol Description

To evaluate the safety and efficacy of OBS treatment administered twice daily for 12 weeks in adolescents.

Eligibility Criteria

Ages 11-17, with histologic evidence of EoE with a peak eosinophil count of >15/HPF, from two of three levels of the esophagus.

Primary Investigator: Michael Hart, M.D.

Contact

Christy Florow, Clinical Research Coordinator
540-985-9723
cmflorow@carilionclinic.org

Functional Constipation (LIN-MD-62)

A multi-center, randomized, double-blind, placebo-controlled, parallel-group, safety and efficacy study of a range of Linaclotide doses administered orally to children, ages 6-17 years, who fulfill modified Rome III criteria for child/adolescent functional constipation (FC).

Protocol Description

Multi-center, randomized, double-blind, placebo-controlled, parallel-group, safety and efficacy study comparing one of three Linactolide doses with placebo in pediatric patients, ages 6 to 17, with a functional constipation diagnosis.

Eligibility Criteria

  • Ages 6-17
  • Able to read and understand the assessments in the e-diary
  • Must meet Rome III criteria for child/adolescent functional constipation
  • Must be compliant with e-diary

Primary Investigator: Michael Hart, M.D.

Contact

Christy Florow, Clinical Research Coordinator
540-985-9723
cmflorow@carilionclinic.org

Irritable Bowel Syndrome and Functional Constipation (LIN-MD-63)

A multi-center, randomized, double-blind, placebo-controlled, parallel-group, safety and efficacy study of a range of Linaclotide doses administered orally to children, ages 7-17 years, with irritable bowel syndrome with constipation (IBS-C).

Protocol Description

Multi-center, randomized, double-blind, placebo-controlled, parallel-group, safety and efficacy study comparing one of three Linactolide doses with placebo in pediatric patients, ages 7 to 17, with IBS and functional constipation diagnosis.

Eligibility Criteria

  • Ages 7-17
  • Able to read and understand the assessments in the e-diary
  • Must meet Rome III criteria for child/adolescent IBS-C
  • Must be compliant with e-diary

Primary Investigator: Michael Hart, M.D.

Contact

Christy Florow, Clinical Research Coordinator
540-985-9723
cmflorow@carilionclinic.org

Ulcerative Colitis (MESALAMINE)

A Phase III, multi-center, randomized, double-blind study to determine the safety and efficacy of MMX® Mesalamine/Mesalazine in pediatric subjects with mild to moderate ulcerative colitis, in both acute and maintenance phases.

Protocol Description

To evaluate the safety and tolerability of a low and high dose of Mesalamine in children and adolescents with mild to moderate ulcerative colitis.

Eligibility Criteria

  • Ages 5-17
  • Diagnosed with mild to moderate ulcerative colitis
  • Able to swallow the study drug whole

Primary Investigator: Michael Hart, M.D.

Contact

Christy Florow, Clinical Research Coordinator
540-985-9723
cmflorow@carilionclinic.org

Bowel Cleansing Prep (BLI800)

A Safety and Efficacy Study of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy.

Protocol Description

To compare the safety, tolerance and efficacy of BLI800 to NuLytely as bowel preparation prior to colonoscopy in adolescent patients.

Eligibility Criteria

  • Male or female subjects between the ages of 12-16 (inclusive)
  • Undergoing colonoscopy for routinely accepted indications
  • Negative pregnancy test as screening, if applicable

Primary Investigator: Michael Hart, M.D.

Contact

Christy Florow, Clinical Research Coordinator
540-985-9723
cmflorow@carilionclinic.org

Pediatric Pulmonology

Pneumonia Study for Adolescents (CEMPRA)

A Phase 2/3, randomized, open-label, multi-center study to determine the safety and efficacy of Solithromycin in adolescents (12-17 years of age, inclusive) and children (≥2 months to <12 years of age) with suspected or confirmed community-acquired bacterial pneumonia.

Protocol Description

This is a Phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with CABP. After informed consent/assent is obtained, subjects will be randomized to receive solithromycin or a comparator drug, administered by mouth (PO) based on weight and age. Pharmacokinetic samples will be collected to assess solithromycin disposition in subjects with CABP. The duration of participation, from the signing of the informed consent form and assent (if applicable), will be up to 40 days.

Eligibility Criteria

  • Written informed consent from parents or other legally acceptable representatives and informed assent from subject (if age appropriate according to local requirements)
  • ≥2 months to 17 years of age, inclusive
  • Requiring hospitalization, emergency room or urgent care visit
  • Presence of CABP

AND

  • Presence of at least 1 of the following:
    • Leukocytosis (≥12,000 white blood cells [WBC]/mm3)
    • Leukopenia (<5000 WBC/mm3)
    • ≥10% immature neutrophils (bands) regardless of total peripheral WBC
    • Elevated inflammatory markers (C-reactive protein or procalcitonin)
    • Oxygen saturation <97% on room air
    • Organism consistent with a typical respiratory pathogen identified from a blood culture or isolated from an appropriate respiratory culture/polymerase chain reaction (sputum in children old enough to produce an acceptable specimen; sample from the lower respiratory tract airways, if performed [e.g., bronchoalveolar lavage]; or pleural fluid culture)

Exclusion Criteria

  • Confirmed or suspected respiratory tract infection attributable to sources other than community-acquired bacterial pathogens (e.g., ventilator-associated pneumonia; hospital-acquired pneumonia).
  • Received >48 hours of potentially effective systemic antibacterial therapy for CABP immediately prior to randomization (exception: clinical or microbiological treatment failure or progression of signs or symptoms of CABP as determined by the investigator).
  • Confirmed or suspected bacterial meningitis.
  • Known active pulmonary tuberculosis.

Primary Investigator: Andre Muelenaer, M.D.

Contact

Kellie Hirt, Clinical Research Coordinator
540-985-9934
kehirt@carilionclinic.org

Faculty
Contact and Careers
Job Postings
FAQs
Is Subspecialty
Off
Education
Residencies Intro
Our program offers a comprehensive curriculum that prepares residents for general or subspecialty practice. Carilion Children’s Hospital is the only dedicated children’s hospital in southwest Virginia and has a catchment area of 1 million people. The hospital-within-a-hospital has a 24-bed pediatric ward, 8-bed PICU, 60-bed NICU, a dedicated pediatric Emergency Department, a pediatric and neonatal transport team, pediatric therapies, seven primary care clinics and 19 subspecialty care clinics.

The Carilion Clinic - Virginia Tech Carilion School of Medicine Pediatric Residency program is accredited by the American Council for Graduate Medical Education. We also participate in the National Residency Matching Program.

Residents have the opportunity to work closely with the students and research scientists from the Virginia Tech Carilion School of Medicine
and the Fralin Biomedical Research Institute. The public-private partnership leverages Virginia Tech’s world-class strength in basic sciences, bioinformatics and engineering with Carilion Clinic’s highly experienced medical staff and rich history in medical education.

Our focus is to train pediatricians who will be equipped to begin a career in general pediatric practice or to confidently enter into fellowship training. We have six residents per year, which allows for individual attention to each resident's educational needs and professional goals.
Residencies

Pediatrics Residency

Is Fellowship
Off
Is Fellowship Accredited
Off
Hero Image Categories
Building
Hero Image Selection
Option 3
Summary
Our focus is on training pediatricians who will be ready for general practice or fellowship training. We have six residents per year, which allows for individual attention to each resident's educational needs and professional goals.
Faculty
Specialty Group
Program Director
Specialty Group
Associate Program Directors
Specialty Group
Department Leadership
Specialty Group
Pediatric Cardiology
Specialty Group
Child Development Clinic and Pediatric Behavioral Health
Specialty Group
Pediatric Critical Care
Specialty Group
Pediatric Endocrinology
Specialty Group
Pediatric Gastroenterology
Specialty Group
Pediatric Genetics
Specialty Group
Pediatric Hematology/Oncology
Specialty Group
Pediatric Neurology
Specialty Group
Pediatric Pulmonology and Allergy
Procedural Exposure

As a program that operates without fellows, our residents have ample opportunities to be hands-on in performing procedures on their patients. Residents also utilize the Carilion Clinic Center for Simulation, Research and Patient Safety (SIM Lab), an 11,000-square-foot training facility that includes a birthing suite and neonate care area, single patient room, operating room, trauma bay, debriefing rooms, classrooms and clinical skills lab. Prior to graduation, pediatric residents are required to obtain competency in the following procedures: 

  • Bag mask ventilation
  • Bladder catheterization
  • Circumcision (may opt out to observe only)
  • Delivery room resuscitation
  • Foreign body removal
  • Incision and drainage of superficial abscesses
  • Immunizations
  • IV line placement
  • Intubation of neonates
  • Laceration repair
  • Lumbar puncture
  • Reduction of simple dislocations
  • Splinting of fractures
  • Umbilical artery/vein catheterization
Overview

Continuing Medical Education is critical to positive outcomes when caring for children. At Carilion Children’s we offer multiple formats for you to participate in our CME and MOC programs.

The Carilion Children’s REACH Network connects regional medical professionals to our health system for professional education, communication and patient follow-up. To better connect with you, we offer live weekly webcasts, a weekly e-newsletter, educational recordings released on our YouTube channel, inpatient transport reviews and other patient follow-up as needed. CME credit is offered for qualifying education.

Join the REACH Network

By joining our network of clinicians, you receive:

  • Access to a community with more than 1,000 clinicians from Virginia, West Virginia, Tennessee and North Carolina
  • Weekly invites to join our Pediatric Grand Rounds webcast (Thursdays at 7:30 a.m.)
  • A weekly e-newsletter with important updates for our network and recordings from our previous webcasts
  • CME credits are available for qualifying material
  • Did we mention it's free to join?

Please contact us at outreach@carilionclinic.org to register.

Hero Image Categories
Pediatrics
Hero Image Selection
Option 2